Search research articles
Contact Us
Filters
Showing results (31-40 of 44) with videos related to
Page
of 5
Sort By:
British Journal of Cancer
|
April 29, 2010
Capecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancer
J Feliu, M J Safont, A Salud, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 21, 2017
MRI assessment and outcomes in patients receiving neoadjuvant chemotherapy only for primary rectal cancer: long-term results from the GEMCAD 0801 trial
U B Patel, G Brown, I Machado, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 10, 2015
Chemoradiation, surgery and adjuvant chemotherapy versus induction chemotherapy followed by chemoradiation and surgery: long-term results of the Spanish GCR-3 phase II randomized trial†
C Fernandez-Martos, X Garcia-Albeniz, C Pericay, et al.
British Journal of Cancer
|
April 15, 2004
Irinotecan plus raltitrexed as first-line treatment in advanced colorectal cancer: a phase II study
J Feliu, A Salud, P Escudero, et al.
Cancer Chemotherapy and Pharmacology
|
October 7, 2019
Correction to: Phase II study to evaluate the efficacy of Trastuzumab in combination with Capecitabine and Oxaliplatin in first-line treatment of HER2-positive advanced gastric cancer: HERXO trial
Fernando Rivera, C Romero, P Jimenez-Fonseca, et al.
Cancer Chemotherapy and Pharmacology
|
March 31, 2019
Phase II study to evaluate the efficacy of Trastuzumab in combination with Capecitabine and Oxaliplatin in first-line treatment of HER2-positive advanced gastric cancer: HERXO trial
Fernando Rivera, C Romero, P Jimenez-Fonseca, et al.
British Journal of Cancer
|
June 20, 2014
First-line bevacizumab and capecitabine-oxaliplatin in elderly patients with mCRC: GEMCAD phase II BECOX study
J Feliu, A Salud, M J Safont, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 7, 2019
Phase II study of high-sensitivity genotyping of KRAS, NRAS, BRAF and PIK3CA to ultra-select metastatic colorectal cancer patients for panitumumab plus FOLFIRI: the ULTRA trial
C Santos, D Azuara, J M Viéitez, et al.
BMC Cancer
|
June 5, 2019
First-line single-agent regorafenib in frail patients with metastatic colorectal cancer: a pilot phase II study of the Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)
A Carrato, M Benavides, B Massutí, et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine
|
June 17, 2017
Dynamic soluble changes in sVEGFR1, HGF, and VEGF promote chemotherapy and bevacizumab resistance: A prospective translational study in the BECOX (GEMCAD 09-01) trial
Estela Pineda, A Salud, E Vila-Navarro, et al.
Page
of 5
Search research articles
Search
Showing results (31-40 of 44) with videos related to
Sort By:
Page
of 5
British Journal of Cancer
|
April 29, 2010
Capecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancer
J Feliu, M J Safont, A Salud, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 21, 2017
MRI assessment and outcomes in patients receiving neoadjuvant chemotherapy only for primary rectal cancer: long-term results from the GEMCAD 0801 trial
U B Patel, G Brown, I Machado, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 10, 2015
Chemoradiation, surgery and adjuvant chemotherapy versus induction chemotherapy followed by chemoradiation and surgery: long-term results of the Spanish GCR-3 phase II randomized trial†
C Fernandez-Martos, X Garcia-Albeniz, C Pericay, et al.
British Journal of Cancer
|
April 15, 2004
Irinotecan plus raltitrexed as first-line treatment in advanced colorectal cancer: a phase II study
J Feliu, A Salud, P Escudero, et al.
Cancer Chemotherapy and Pharmacology
|
October 7, 2019
Correction to: Phase II study to evaluate the efficacy of Trastuzumab in combination with Capecitabine and Oxaliplatin in first-line treatment of HER2-positive advanced gastric cancer: HERXO trial
Fernando Rivera, C Romero, P Jimenez-Fonseca, et al.
Cancer Chemotherapy and Pharmacology
|
March 31, 2019
Phase II study to evaluate the efficacy of Trastuzumab in combination with Capecitabine and Oxaliplatin in first-line treatment of HER2-positive advanced gastric cancer: HERXO trial
Fernando Rivera, C Romero, P Jimenez-Fonseca, et al.
British Journal of Cancer
|
June 20, 2014
First-line bevacizumab and capecitabine-oxaliplatin in elderly patients with mCRC: GEMCAD phase II BECOX study
J Feliu, A Salud, M J Safont, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 7, 2019
Phase II study of high-sensitivity genotyping of KRAS, NRAS, BRAF and PIK3CA to ultra-select metastatic colorectal cancer patients for panitumumab plus FOLFIRI: the ULTRA trial
C Santos, D Azuara, J M Viéitez, et al.
BMC Cancer
|
June 5, 2019
First-line single-agent regorafenib in frail patients with metastatic colorectal cancer: a pilot phase II study of the Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)
A Carrato, M Benavides, B Massutí, et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine
|
June 17, 2017
Dynamic soluble changes in sVEGFR1, HGF, and VEGF promote chemotherapy and bevacizumab resistance: A prospective translational study in the BECOX (GEMCAD 09-01) trial
Estela Pineda, A Salud, E Vila-Navarro, et al.
Page
of 5